Inhibition of chemokines and cytokines in subjects with CLL after treatment with entospletinib. Serum levels of BCR-mediated chemokines/cytokines, including CCL3/MIP-1α, CCL4/MIP-1β, CCL22/MDC, and tumor necrosis factor α, were measured on day 1 before entospletinib treatment and on days 8 and 29 by Luminex (Life Technologies/Thermo Fisher Scientific, Waltham, MA) immunoassays (n = 40). Entospletinib reduced mean plasma levels of all measured chemokines/cytokines over time (nominal P < .0001).